A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Recruiting

Phase 2

ElismetrepA Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Sponsor:

Kallyope Inc.

Code:

NCT06848075

Conditions

Acute Migraine

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Elismetrep (K-304) Dose Level 1

Elismetrep (K-304) Dose level 2

Elismetrep (K-304) Dose level 3

Elismetrep (K-304) Dose level 4

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-20. This information was provided to ClinicalTrials.gov by Kallyope Inc. on 2025-04-23.